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ABSTRACT 
 
Influenza A is a single-stranded, multi-segmented, negative sense RNA 
virus of the family Orthomyxoviridae and is the causative agent of seasonal 
Influenza. Influenza viruses cause significant impacts on a global scale with 
regard to public health and economics. Annual influenza virus infections in the 
United States account for over 200,000 hospitalizations, up to 49,000 deaths 
(cdc.gov), and an economic burden of $87.1 billion (Molinari, et al., 2007). 
Influenza A virus has caused several pandemics since the turn of the 20th 
century. The effects of Influenza on public health and economics, compounded 
with low efficacy of the annual vaccine and emerging antiviral resistance, brings 
to light the need for an effort to stem these impacts, prevent pandemics, and 
protect public health by developing novel treatments. 
This project proposes an alternative approach to combatting Influenza by 
targeting crucial host factors hijacked during infection that, if inhibited, 
significantly impair viral RNA expression, but result in low toxicity to the host. The 
host factors we examined include RNA export factors (XpoT and Xpo5) and RNA 
helicases (UAP56 and URH49). We selected the paralogs URH49 (DDX39A) and 
UAP56 (DDX39B) because previous studies suggest differing roles during 
Influenza infection, but we theorize that their high degree of sequence similarity, 
similar function, and association with many of the same cellular factors may allow 
them to substitute for one another if one is knocked down or inhibited. 
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CRISPR was considered as the primary method to evaluate the effect of 
knockout of these factors on viral RNA expression and host cell toxicity. CRISPR 
is an RNA guided mechanism for gene editing and was to be used to make null 
mutations in the targeted host genes. However, CRISPR proved to be a 
significant challenge and while we could not conclusively confirm whether the 
CRISPR plasmids were effective at targeting our genes of interest, our initial 
results were not promising and we did not pursue this approach further. As an 
alternative, host RNA export factors were evaluated using siRNA to knockdown 
the factor prior to influenza infection. RNA was then analyzed by reverse 
transcription quantitative polymerase chain reaction (RT-qPCR). The potential of 
inhibiting UAP56 or URH49 as a novel therapeutic target was determined using a 
visual assessment of cell death. 
We found that siRNA-mediated knockdown of XpoT and Xpo5 did not 
have any impact on viral RNA synthesis early during infection. siRNA against 
UAP56 and DDX39 (targets both UAP56 and URH49) resulted in significant 
impairment in viral RNA synthesis, confirming previously established work 
suggesting that UAP56 and URH49 have important roles during infection. 
Importantly, these helicases play an interferon (IFN) independent role to enhance 
viral replication, as indicated by analysis in IFN deficient VERO cells. A viability 
assay relying on trypan blue exclusion did not yield trustworthy results, so a 
visual assessment of cell death was done. The visual assessment confirms 
previously-established observations that Nxf1 (mRNA export factor) siRNA 
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treatments result in a high degree of cell death, indicating the toxic nature of Nxf1 
inhibition. Cells treated with UAP56 or DDX39 siRNAs demonstrated little to no 
additional toxicity compared to the non-target control, suggesting they can be 
inhibited to serve as antiviral targets.  
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CHAPTER ONE 
BACKGROUND AND SIGNIFICANCE 
 
Societal Impacts of Influenza A Virus 
Influenza viruses have a unique history and origin: as early as the 15th 
century in Italy, there was an epidemic which was attributed to an “influence of 
the stars.” The epidemic was, in fact, caused by what we now know to be 
Influenza virus. It was because of this very epidemic that the virus became 
known as Influenza, its name taken from the Italian word influenza, which means 
“influence”. However, that is not the only epidemic (or pandemic) that Influenza 
has caused in its long history. The first pandemic was recorded in 1580 and at 
least four other pandemics were recorded later in the 18th century. It was not until 
1933 that Smith, Andrews, and Laidlaw were able to isolate Influenza A from 
ferrets; Influenza B was isolated by Francois in 1936 (cdc.gov). 
In addition to the pandemics of the 18th century, Influenza A has also 
caused several pandemics since the turn of the 20th century, including the 1918 
Spanish Flu, 1957 Asian Flu, 1968 Hong Kong Flu, and 2009 Swine Flu. The 
Spanish Flu pandemic was incredibly widespread and had a higher mortality rate 
than other strains, with 20-40% of the worldwide population becoming ill and an 
estimated 50 million dying from the virus or complications associated with 
infection. The Asian Flu pandemic proved to be a classic example of “second 
wave” infections that are common among pandemics; even when the worst 
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seemed to be over, the virus made a resurgence shortly afterward, targeting a 
different group among the population. The Hong Kong Flu pandemic was both 
not as widespread as the Asian Flu and had even lower mortality in the United 
States, because its arrival coinciding with school children’s vacation time in 
December (less close contact because they were not at school together), and 
advancements in antibiotic development curbed the effects of secondary 
bacterial infection. The Swine Flu pandemic began in the Spring, which gave the 
CDC little time to develop a vaccine; for these reasons, estimates put the number 
of H1N1-related infections between April 2009 and April 2010 at 43 million to 89 
million and over 12,000 H1N1-related deaths (cdc.gov, 2011). 
Influenza epidemics and pandemics are associated with antigenic drift and 
antigenic shift, which are important concepts related to genetics and the 
mutability of genetic information. Epidemics are mainly associated with antigenic 
drift, where a point mutation in a gene segment coding for a surface protein 
causes a minor change in protein structure. These changes result in a virus that 
can escape neutralizing antibodies, resulting in incomplete protection. A classic 
example of antigenic drift influencing Influenza epidemics involves the transition 
of A/Wuhan/359/95 (H3N2), a relative to the 1968 Hong Kong H3N2 strain, into 
A/Sydney/5/97 (H3N2) during the 1997-1998 flu season. The A/Sydney strain, 
which was still very similar to A/Wuhan, had changed enough that the vaccine 
administered for the flu season had little effect and became the predominant 
strain during the following season (cdc.gov, 2016). Pandemics are mainly 
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associated with antigenic shift, a much more significant change in genetic 
makeup. In the case of Influenza, antigenic shift typically occurs when multiple 
viruses infect a cell and their segments shuffle (reassortment), resulting in 
viruses that can contain completely new segments encoding very different 
surface antigens. The 2009 Swine Flu is a recent example of a virus formed by 
gene segment shuffling that resulted in a novel H1N1 strain which caused a 
major pandemic. The pandemic began early in Spring when there was no 
vaccine available and was characterized by morbidity and mortality far above 
expected values for the time of year. A 2011 study estimated that pandemic 
H1N1 resulted in more than 60 million cases of illness in America, 270,000 
hospitalizations, and 12,500 deaths. Since the virus antigen had not been seen in 
recent years, 90% of these hospitalizations and deaths occurred in individuals 
under the age of 65. The low incidence of hospitalization of individuals older than 
the age of 65 is most likely attributed to existing immunity when this antigen was 
previously circulating. Typical seasonal influenza, however, causes 90% of 
hospitalizations and deaths in individuals over the age of 65 (cdc.gov, 2016). 
Influenza viruses cause significant impacts on a global scale with regard 
to public health and economics. Annual influenza virus infections in the United 
States account for over 200,000 hospitalizations, up to 49,000 deaths (cdc.gov, 
2016), and an economic burden of $87.1 billion (Molinari, et al., 2007). 
Worldwide, influenza virus infections result in 3-5 million cases of severe illness 
and 290,000-650,00 deaths annually (who.int). Therefore, it is pertinent that an 
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effort be put forth to stem these impacts, prevent pandemics, and protect public 
health by developing novel influenza treatments.  
 
Influenza A Virus Biology 
Influenza A is a member of Orthomyxoviridae, whose other members 
include the clinically and economically relevant Influenza B, Influenza C, 
Thogoto, Quaranfil, and Infectious Salmon Anemia viruses (Hutchinson, 2013). 
Influenza A is an enveloped, negative-sense, single-stranded RNA virus with 
eight genome segments that code for at least 11 unique proteins. The genome of 
Influenza A is packaged as viral ribonucleoproteins (vRNPs) that consist of one 
heterotrimeric RNA-dependent RNA polymerase (RdRP: PA, PB1, and PB2) and 
multiple nucleoproteins (NP) bound to a single genome segment. The vRNPs are 
encapsidated by a matrix protein (M1) and enveloped by a membrane containing 
Hemagglutinin (HA), Neuraminidase (NA), and proton channels (M2). There are 
18 distinct variants of HA, and 11 for NA (cdc.gov, 2017). The virus also 
expresses three other non-structural proteins that range in function from nuclear 
export (NS2/NEP) to anti-viral response subversion (NS1) and alveolar 
macrophage destruction (PB1-F2) (O’Neill et al., 1998; Hale et al., 2008; 
Coleman, 2007, respectively). 
Infection by the virus begins by receptor-mediated endocytosis of the 
virion after the binding of HA to terminal sialic acid residues of glycoproteins on 
the surface of target cells, distinguishing between α-2,6- and α-2,3-linked 
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glycoproteins in humans and avian species, respectively. It is important to note, 
however, that α-2,3-linked glycoproteins exist in human lung epithelium, but only 
in the lower respiratory tract, which is generally inaccessible to avian-specific 
viruses. HA exists as a trimer with two regions of distinct structure, with the head 
region containing the binding domain for the sialic acid receptor. Host serine 
proteases facilitate cleavage of HA into HA1 and HA2, with HA1 containing 
frequently-changing antigen sites, while HA2 facilitates membrane fusion. The 
endocytic vesicle fuses with an acidified late endosome, resulting in changes to 
internal and external viral proteins: the change in pH results in destabilization of 
internal matrix protein-protein interactions (via passage of hydrogen ions through 
M2 ion channels) and conformational change in external HA2, causing uncoating 
of the genome, the viral envelope to fuse with the late endosome, and release 
the vRNPs into the cytoplasm (Bouvier, et al., 2008). Nuclear localization signals 
(NLS) direct the cell to translocate the vRNPs to the nucleus where transcription 
begins (Bouvier, 2008). While the RdRP is capable of  
Transcription of viral mRNAs is not facilitated by the host RNA polymerase 
II because it is a DNA-dependent enzyme. Instead, the encoded viral RNA-
dependent RNA polymerase performs this function, albeit in a very unique way. 
The viral polymerase is not capable of recruiting capping machinery, so instead it 
cleaves 5’-capped RNA fragments from nascent cellular mRNAs in a process 
called “cap snatching” (Hutchinson, 2013). Similarly, it cannot recruit Poly-A 
Polymerase, a crucial enzyme required for synthesis of the poly-A tail on host cell 
6 
 
transcripts. Instead of snatching poly-A tails, a poly-U (poly-uracil) tract is 
encoded in each of the viral genome segments. Stuttering over this poly-U tract 
is the mechanism by which the virus synthesizes its poly-A tail (Bouvier, 2008). 
After cap snatching and poly-adenylating, viral mRNAs are exported to the 
cytoplasm. The HA, NA, and M2 envelope proteins are synthesized and sorted 
by membrane-bound ribosomes and trafficked to the plasma membrane 
(Bouvier, 2008). The polymerase subunits (PA, PB1, PB2) and NP are crucial for 
vRNP formation in the nucleus, but they are synthesized in the cytoplasm; the 
virus circumvents this problem by having an NLS on each subunit, which allows 
for interaction with importins. PA and PB1 are imported as a dimer while PB2 and 
NP are imported as separate monomers. These importins are also hypothesized 
to function as chaperones for PB1 and NP during assembly of the vRNP 
(Hutchinson, 2013). 
During the course of infection, the multifunctional non-structural protein 
NS1 (with proposed dimerization states) serves a plethora of functions, including 
control of viral mRNA splicing, enhancement of viral mRNA translation, host 
immune response suppression, and strain-dependent pathogenesis (for review of 
NS1 function see Hale, 2008). 
NS2, also known as Nuclear Export Protein (NEP), was once thought to 
be just a mere export protein. In reality, like its NS1 counterpart, it is quite 
multifunctional. Early studies implicated NS2 in the export of vRNPs during 
replication, but other studies have implicated it in regulation of viral mRNA and 
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antigenomic cRNA (an intermediate RNA used as a template for genome 
segment synthesis), adaptation of H5N1 (avian flu) in mammalian hosts, and 
release of budding virions from the host cell. NS2 is also highly conserved across 
all sequenced Influenza A strains with overall 93.4% amino acid identity and 
96.3% C-terminal α-helix amino acid identity. NS2 interacts with Crm1 and its 
cofactor, RanGTP, through its NES to facilitate export of vRNPs. When Crm1 
binds, it is believed that RanGTP binds to a separate yet unknown site on NS2. 
Although there is support for NS2 co-localizing with the vRNP during export, 
some argue that it not a central factor in the process. Regardless, a potential role 
for NS2 as a vRNP export factor cannot be easily dismissed (Paterson, 2012). 
Once the vRNPs are exported to the cytoplasm, they are packaged into a 
new virion and exit through budding of the plasma membrane. Once the virus 
has budded from the cell, HA continues to anchor it to the cell surface due to its 
sialic acid binding activity. Neuraminidase (NA) exists as a mushroom-shaped 
tetramer that targets terminal sialic acid residues of glycoproteins and 
gangliosides. Its cleavage activity serves two purposes: (1) to release the new 
virus particles from the cell surface and (2) prevent virus particle aggregation by 
cleaving these residues on the surface of the viral envelope, enhancing infectivity 
(Bouvier, et al., 2008). 
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Current Treatments and Preventative Measures 
The only current preventative measure against influenza virus infection is 
the trivalent or tetravalent annual vaccine. The composition of the vaccine 
depends on which strains are believed to be most prominent during the next flu 
season (cdc.gov, 2017). Although vaccination has revolutionized healthcare and 
the prevention of debilitating diseases such as polio and smallpox, there is yet to 
be a universal vaccine identified to protect against all subtypes of influenza and 
annual vaccination is required. Producing an annual vaccine on a large scale 
takes about six months of preparation; production needs to begin in March (and 
sometimes as early as January), so that the vaccine will be available by October 
(cdc.gov, 2017). Vaccination, overall, will never cease to be a valuable source of 
protection against infection, but there are several evident shortcomings to the 
annual flu vaccine, specifically, that affect its reliability to provide protection. The 
long period of time required to produce a vaccine means that they are of little use 
in an emerging viral pandemic. Additionally, records starting in 2004 show an 
40% average efficacy of the vaccine to protect, but the 2014-2015 flu vaccine 
only had 19% efficacy due to antigenic drift of circulating strains during the 
course of vaccine development, leaving the vaccine less effective (cdc.gov, 
2018). Vaccine protection also relies upon the immune system to recognize 
antigens and elicit a response specifically to them; if an individual suffers from an 
immune deficiency or they are genetically predisposed to having poor recognition 
of antigens, immunity may not be conferred. For all vaccines, our own genetics 
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and health history have a significant impact on the protective capabilities of the 
vaccine. However, in the case of influenza virus, the genetic variation in the virus 
over time has a significant impact in the protective capability of the vaccine, 
which makes it a protective measure that has variable efficacy year to year. 
Since annual vaccination is not enough to protect against influenza virus, antiviral 
treatments are required to stop viral spread.  
Several antiviral drugs specific to influenza have been developed over the 
last 50 years. Amantadine and Rimantadine, whose mechanism of action 
involves blockage of the viral M2 ion channel, were the first generation of drugs 
used to treat influenza virus infection. Another class of drugs, which includes 
Oseltamivir, Zanamivir, and Peramivir, specifically inhibit cleavage of sialic acid 
by Neuraminidase and prevent virus release from the cell (cdc.gov, 2018). 
Antiviral resistance has already been observed in strains of Influenza. 
According to the CDC, resistance to the adamantane class of drugs (Amantadine 
and Rimantadine) is widespread amongst all Influenza strains and 1.6% of H1N1 
strains during the 2014-2015 flu season were resistant to Oseltamivir and 
Peramivir, meaning the genes encoding resistance are already circulating 
(cdc.gov, 2018). Although resistance to Neuraminidase inhibitors has not been 
observed in other influenza virus strains, the fact remains that resistance is a 
problem that will eventually lead to these drugs becoming useless. 
One way in which viruses in general achieve drug resistance is through 
rapid evolution due to the short replication time; influenza virus can produce 
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1,000–10,000 particles per infected host in as little as 16 hours (Harvard 
Bionumbers, 2010). Additionally, administration of drugs creates an environment 
selective for resistant viruses. For examples, the DNA-dependent RNA 
polymerase of Human Immunodeficiency Virus (HIV) has low fidelity, 
accelerating the evolution of the virus when under selective pressure. A cocktail 
of drugs to treat the virus are effective for a period of time, but viral replication is 
so fast and produces so many varied viruses, termed quasi-species, that 
resistance can emerge before the virus can be cleared from the body. In light of 
antiviral drug resistance and the unreliable nature of the yearly influenza vaccine 
to protect against infection, an alternative approach must be considered that 
could potentially circumvent both these shortcomings. 
 
An Alternative Approach to Combat Influenza 
A universal truth related to all viruses is that they require a permissive host 
cell for replication. Some viruses, such Polyomaviruses, require the host to be 
mitotically active so they can access the nucleus and hijack the replicative 
machinery. Others, such as Hepatitis viruses, have liver cell-specific promotor 
sequences (targeted by liver-specific transcription factors) that only allow them to 
replicate within hepatocytes. In both of these examples, the viruses need to 
hijack cellular machinery to transcribe their genes and replicate their genome. 
Inhibition of cellular factors as opposed to viral targets is an alternative approach 
to inhibit viral infection. The major advantage to inhibiting hijacked host proteins 
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instead of viral proteins is that mutation of the drug target cannot occur during 
infection, decreasing the likelihood of selection for antiviral resistance. However, 
if the host target is essential, this could result in harm to the host cell. Still, cells 
often have multiple redundant proteins to provide similar function. In this 
alternative approach, we aim to identify a host factor which plays a redundant 
role in the host cell but an essential role in viral replication, thereby providing a 
useful host target to inhibit viral infection.  We are interested in examining host 
RNA processing and export factors to determine if any can be targeted to inhibit 
influenza.  
 
UAP56, URH49, and the DEAD-box Family of Helicases 
Helicases as a whole act across a general or specific set of substrates 
and have a diverse array of functions, including separation of duplexes, regulated 
binding to single- or double-stranded DNA or RNA, remodeling of complex 
structures in RNA or RNA-protein complexes, and chaperoning self-splicing 
elements of mRNAs to within proximity of each other. The general mechanism of 
activity is by binding to a single strand and separating duplexes by translocating 
in a 3’→5’ direction by ATP hydrolysis. Most helicases have a high degree 
processivity, meaning that the probability of the helicase remaining associated 
and continuing its activity after a successful cycle of ATP hydrolysis, 
translocation, and strand separation is high. For many helicases, they are 
capable of translocating hundreds or thousands of base pairs before dissociating. 
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DEAD-box helicases, however, have demonstrated poor helicase activity. Their 
effectiveness decreases substantially when they need to separate more than 10-
15 base pairs at a time, but this is of little consequence with the consideration 
that RNA rarely has helices longer than 10 base pairs or so (Jarmoskaite, 2011). 
The DEAD-box RNA helicase family of proteins, which include USP56 and 
URH49, is characterized by the Asp-Glu-Ala-Asp (D-E-A-D) motif common to this 
group. The local RNA remodeling activity of DEAD-box helicases makes them 
distinct from other groups of helicases, especially when only small select 
sections of an RNA need to be remodeled, as opposed to the global structure. 
UAP56 and URH49 function as pre-mRNA splicing factors and are crucial 
components of export complexes. UAP56 aids in the hTREX complex (couples 
transcription elongation to nuclear export) while URH49 aids in the hAREX 
complex (alternative RNA export) (Yamazaki, 2010). Both helicases have CRM1-
independent nucleocytoplasmic shuttling activity and interact with REF, an 
established spliced- and unspliced-RNA export factor (Thomas, et al., 2011). 
UAP56 has also been shown to be essential in the function of the U2AF65 
splicing complex, specifically in the interaction with the branch point adenine, the 
nucleotide responsible for the nucleophilic attack that forms the lariat structure in 
group II introns (Fleckner, et al., 1997). As a whole, these helicases have 
redundant functions in the host cell, but essential functions in Influenza virus 
infection, making them potential novel antiviral targets. I am interested in 
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determining if UAP56, URH49, or both function as NP chaperones during 
influenza virus infection and can serve as useful antiviral targets. 
. Previous research has implicated UAP56 as a hijacked host protein 
during Influenza infection. UAP56 was shown to associate with free NP and 
promote viral RNA synthesis in vitro (Momose, et al., 2001) by chaperoning NP 
onto the viral RNA during replication (Kawaguchi, et al., 2011). This function of 
UAP56 as a facilitator for viral RNA synthesis was also observed after eliminating 
its helicase through a targeted R365Q mutation, suggesting that its helicase 
activity is not required for its function in Influenza infection (Momose, et al., 
2001). A paper by Wisskirchen in 2011 implicated UAP56, as well as its paralog 
URH49, in Influenza infection by their association with NP. Although UAP56 and 
URH49 share over 90% protein identify, the authors found only UAP56 was 
involved in the downregulation of dsRNA products during viral infection. These 
studies highlight several ways UAP56 and URH49 may be used to subvert the 
host cell and facilitate viral activity; more importantly, it suggests the two paralogs 
may maintain varied functions during viral infection. 
 
RNA Export Factors: Nxf1, Crm1, XpoT, and Xpo5 
RNA export from the nucleus is an essential function of cells. There are 
different export factors for different kinds of RNA; specifically, Nxf1 (mRNA), 
Crm1 (rRNA), XpoT (tRNA) and Xpo5 (miRNA). In the case of Influenza A, Nxf1 
is implicated in some but not all influenza mRNA nuclear export (Larsen et al, 
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2014) while Crm1 is not involved in influenza mRNA nuclear export but is 
required for vRNP export during virion assembly (Elton et al, 2001). Inhibition of 
either will inhibit viral infection, but is also detrimental to the host cell. Given not 
all influenza mRNAs export via Nxf1, we aimed to decipher the importance of 
XpoT and Xpo5 for influenza infection.  
In the cell, there are two main pathways through which mRNAs can exit 
the nucleus: usage of the Nxf1-Nxt1/Tap-p15 heterodimer or Crm1/Xpo1. Nxf1 is 
unique in that it has an RNA-binding domain, but it normally maintains a closed 
conformation, which makes it inefficient in binding RNA on its own. When the 
Transcription-Export Complex 1 (TREX1) is recruited to mRNA (in a splicing-
dependent manner in humans), Nxf1 binds to TREX and a set of three SR 
proteins, adopting an open conformation and becoming able to efficiently bind 
RNA. The function of Nxt1 is still under investigation, but what is understood is 
that it stimulates binding of the Nxf1-RNA complex to nucleoporin p69. RNA is 
exported with the help of Dpb5 and Gle1 on the cytoplasmic side (for review see 
Carmody, 2009).   
Crm1 cannot bind RNA directly. Instead, it relies on adaptor proteins in 
order to execute its functions. Crm1 interacts with many Ran-family proteins, 
including Ran-BP3 (binds RNA) and Ran-GTP. Through the interaction of these 
Ran proteins with the nuclear pore complex, mRNA is translocated to the 
cytoplasm (for review see Okamura, 2015). Crm1 is also involved in export of 
rRNA to the cytoplasm (Carmody, 2009).  
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XpoT (Los1 in yeast) is the principle factor involved in export of tRNA in 
vertebrates. Work in yeast with los1Δ strains shows an accumulation of 
processed, intron-containing tRNAs; the absence of splicing is due to the tRNA-
specific splicing machinery existing on the outer mitochondrial membrane. 
Interestingly, los1Δ strains are viable, the A. thaliana XpoT homolog is 
nonessential, and insects lack an XpoT homolog but still manage to export tRNA, 
which suggests an additional novel export factor for tRNA. Xpo5 has been 
identified as an export factor for tRNA in Drosophila and yeast, but vertebrate 
Xpo5 is the principle factor in miRNA transport, so its role in tRNA export in 
humans is considered to be minor at best (Okamura, 2015). 
Although Xpo5 exports tRNA in Drosophila and yeast, its primary function 
is to export miRNAs, small RNAs that are used for post-transcriptional regulation 
of gene expression. Mature miRNAs are synthesized as pri-miRNA (primary 
miRNA) by RNA polymerase II (RNAPII) and contain a local hairpin structure. 
Although RNAPII is classically associated with cellular mRNAs, pri-miRNAs are, 
in fact, 5’-capped and polyadenylated. Processing begins in the nucleus and 
ends in the cytoplasm. The canonical processing pathway involves Drosha-
DGCR8 in the nucleus and Dicer-Argonaute in the cytoplasm; Drosha-DGCR8-
independent, Dicer-independent, and TUTase-dependent pathways also exist for 
miRNA processing, often times for very specific miRNA products (Okamura 
2015). 
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Overall, though each export factor functions as a principle factor for each 
class of RNA (mRNA, rRNA, tRNA, and miRNA), there is also a significant 
amount of overlap in the roles each can play. This may make it possible to 
identify a viable host target for inhibition. 
 
RNA Technology: RNAi, siRNA, and CRISPR 
RNAi, short for RNA interference, is a natural process involving small (20-
30 nucleotides) non-coding RNAs (ncRNAs) that are used to control gene 
expression. Originally discovered as a microRNA (miRNA) in C. elegans, 
research on RNAi has revealed that up to 5% of the human genome is dedicated 
to the production of these ncRNAs that regulate the expression of least 30% of 
our genes, including those involved in cellular proliferation, differentiation, and 
chromatin packaging. RNA technology based on RNAi, termed siRNA (small 
interfering RNA), activates RNAi pathways to downregulate gene expression, but 
the RNAs are synthetic and exogenously supplied (for review see Wilson, 2013). 
For siRNA inhibition, double stranded siRNAs ~ 21-25 nucleotides with 2-
base 3’ overhangs on either end are transfected into cells and processed in the 
cytoplasm to associate with the RISC complex. The complex contains Dicer, 
Argonaute, and additional RNA Binding Proteins. Argonaute binds the 5’ and 3’ 
ends of a single strand (guide strand) in the dsRNA and discards the other 
(passenger strand). The RISC complex binds ssRNA, looking for partial 
complementarity, at minimum. This results in translational inhibition and often is 
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followed by deadenylation and degradation of the target mRNA occurs. (Wilson, 
et al., 2013). 
Another RNA technology, CRISPR, which stands for Clustered Regularly 
Interspaced Short Palindromic Repeats, was originally discovered in the 1980s in 
E. coli, but its function was elucidated only as recently as 2007 when researchers 
discovered that Streptococcus thermophilius was able to develop resistance to 
bacteriophage by incorporating a fragment of the phage genome into its CRISPR 
locus (Barrangou, et al., 2007). More recently, Mimivirus, a large virus of 
amoeba, was discovered to have a CRISPR-like system to defend it from 
virophages (Levasseur, et al., 2016). This system, specifically type II, utilizes 
Cas9, a protein with DNA-binding, RNA-binding, and endonuclease activities, 
and a guide RNA (gRNA) specific to the sequence being targeted. Cas9 
recognizes the protospacer adjacent motif (PAM) sequence NGG and, upon 
recognition, allows the gRNA to invade the DNA strand and check for 
complementarity. If the DNA is complementary, then Cas9 causes a blunt-end 
cleavage upstream of the PAM sequence. Non-homologous end joining becomes 
active and, in the event CRISPR is targeting a gene, causes insertions or 
deletions at the target site, effectively disrupting the gene. Variants of Cas9 have 
been developed that change its activity to that of a nickase, which initiates the 
high-fidelity homology directed repair (HDR) pathway. With the addition of a 
repair template, a gene can be modified while simultaneously reducing off-target 
effects (Cong, et al., 2013). 
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Here, I employed both RNA technologies to examine the roll of host RNA 
processing and export factors on influenza replication. CRISPR was attempted 
with little success to generate knock out UAP56 and URH49 cell lines. Since 
CRISPR was not successful we also employed siRNAs to downregulate these 
RNA helicases and additional host nuclear export factors. RNAi routinely 
inhibited target gene and we discuss the effects on viral RNA replication. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Cells 
A549 (Human Lung Adenocarcinoma) and Vero (African Green Monkey 
Kidney) were purchased from ATCC and cultured in the following conditions: 
37oC, 5% CO2 in DMEM with 10% FBS (fetal bovine serum). 
 
CRISPR Plasmids 
Plasmids encoding CRISPR Cas9 and guide RNAs targeting UAP56 and 
URH49 (five for each gene) were provided by Horizon Discovery. Guide RNA 
sequences are withheld as proprietary information. Plasmids were transformed to 
E. coli DH5α and purified by Qiagen plasmid miniprep kit per the manufacturer’s 
protocol. 
DNA Transfection Protocol 
For preliminary screening of CRISPR plasmids, A549 cells were seeded 
into 6-well plates at 0.3x106 cells/mL. Cells were transfected at 40-50% 
confluency with Mirus LT-1 transfection reagent and allowed to incubate with 
CRISPR plasmid for 72 hours. Cells were harvested for further analysis. 
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FACS 
A549 cells seeded into T-25 flasks with approximately 1.76x105 cells. 
Cells were transfected at approximately 40-50% confluency with a 2:1 ratio of 
Mirus LT-1 transfection reagent (μL) to CRISPR-encoding plasmid DNA (μg). 
Cells were allowed to incubate for 72 hours before harvest. GFP expression from 
eGFP plasmid was used to evaluate if transfection was successful. 
Sorting GFP and CRISPR Expressing Cells – FACS 
Cells were collected 72 hours post transfection and prepped for FACS at 
University of California, Riverside (UCR). Cells were collected by trypsinization 
and centrifuged at 300xg for 7.5 minutes at 4oC. Trypsin was removed and cells 
were washed in sort buffer. Cells were centrifuged again under the same 
conditions. Sort buffer was removed and cells were resuspended in sort buffer to 
achieve a maximum concentration of 8.0x106 cells/mL. Cells were transported to 
UCR on ice and sorting was performed using FACS Aria with GFP expression as 
the means for identifying cells expressing CRISPR. 
Composition of Buffer Used for Resuspension of CRISPR Cells Before Sorting 
1x Phosphate Buffered Saline (Ca2+/Mg2+-free to reduce intracellular 
adhesion), 1mM EDTA, 25mM HEPES (pH 7.0), 1% inactivated fetal bovine 
serum. Sort buffer was sterilized using a 0.2μm filter. 
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Analysis with Surveyor Nuclease 
Genomic DNA Extraction 
CRISPR-treated GFP-positive cells were centrifuged at 300xg for 7.5 
minutes at 4oC and buffer was removed. Genomic DNA was extracted with 
Invitrogen PureLink Genomic DNA Mini Kit according to manufacturer’s 
specifications. 
PCR Amplification of Target Regions of UAP56 and URH49 
Primers were ordered from Fisher Scientific for UAP56 and URH49 with 
the follow sequences: 
UAP56 Forward: 5’-CTTTGCTGTTCCTCAATCCC-3’ 
UAP56 Reverse: 5’-AGCTTTAGCCTCCTCCAGAT-3’ 
URH49 Forward: 5’-CTGTGGGCACTTTCCAGTTA-3’ 
URH49 Reverse: 5’-GGAGGGTGTTCTGTCTGT-3’ 
The target region of UAP56 or URH49 was amplified in a 50μL reaction 
using 2X PCR master mix (Promega) and 15-20ng of genomic DNA. The 
program for amplification for 35 cycles was as follows: 
1. Initial denaturation: 95oC for 60 seconds 
2. Denaturation: 95oC for 30 seconds 
3. Annealing: 55oC for 40 seconds 
4. Extension: 72oC for 75 seconds 
5. Final extension: 72oC for 5 minutes 
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10μL of PCR product was run on a 1% agarose gel for 40 minutes at 120V 
to assess the success of the reaction. 
Treatment with Surveyor Nuclease 
10μL of each PCR reaction using genomic DNA from CRISPR-treated 
GFP-positive cells was mixed with 10μL of PCR reaction using genomic DNA 
from untreated cells. PCR products were denatured and allowed to re-anneal to 
form hybrid DNA strands using a thermocycler with the following program: 
1. 95oC for 10 minutes 
2. 95oC → 85oC, -2.0oC/sec ramp, hold for 1 minute 
3. 85oC → 75oC, -3.0oC/sec ramp, hold for 1 minute 
4. 75oC → 65oC, -3.0oC/sec ramp, hold for 1 minute 
5. 65oC → 55oC, -3.0oC/sec ramp, hold for 1 minute 
6. 55oC → 45oC, -3.0oC/sec ramp, hold for 1 minute 
7. 45oC → 35oC, -3.0oC/sec ramp, hold for 1 minute 
8. 35oC → 25oC, -3.0oC/sec ramp, hold for 1 minute 
9. 25oC → 4oC, hold indefinitely 
The 20μL volume of heteroduplex DNA was treated with Surveyor 
Nuclease from Integrated DNA Technologies according to their protocol. Treated 
DNA was run on a 1% agarose gel to observe cleavage events. 
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siRNAs 
siRNA SMARTpools targeting Nxf1, Crm1, XpoT, Xpo5, UAP56, and 
DDX39 were purchased from Dharmacon. Cells were seeded at 0.3x106 cells/mL 
into 6-well plates. Cells at 50%-70% confluency were transfected with 25nM 
siRNA for 48 hours using Dharmacon reagent according to manufacturer’s 
protocol. 
 
Influenza Infection, RNA Extraction, and Quantitative PCR 
48 hours post transfection, cells were infected with Influenza virus at an 
MOI of 4 for 4 hours, or mock infected. Egg amplified influenza virus was 
prepared in serum-free media with 1μg/mL N-acetyltrypsin. Media was removed 
from cells prior to infection and virus suspension was allowed to attach to cells 
for 1 hour. Virus suspension was removed and DMEM with 2.5% FBS was added 
to the cells for 3 hours. Media was then removed, cells washed with Ca2+/Mg2+-
free PBS, and cells were collected with a cell scraper. 
RNA Extraction, Concentration, and Integrity 
RNA was isolated using Trizol according to manufacturer’s protocol. RNA 
concentration was determined using Nanodrop ND-1000 and a 1% agarose/1% 
bleach gel was made to assess the integrity and confirm concentration of the 
RNA. RNA was resolved on the gel at 120V for 1 hour. 
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Reverse Transcription 
1000ng of RNA was used for reverse transcription with the AMV RT kit 
from Promega using oligo dT primer. Prior to reverse transcription, RNA was 
denatured at 70oC for 10 minutes in a water bath. The 20μL reaction was 
performed at 42oC in a water bath for 1 hour. The AMV RT enzyme was 
denatured at 95oC for 5 minutes, then samples were allowed to cool on ice for 5 
minutes. 80μL of 10mM Tris (pH 7.5) was then added to the cDNA. 
Quantitative PCR 
Quantitative PCR was performed using the StepOne Plus Real Time PCR 
system (Applied Biosystems) using SYBR Green master mix from Applied 
Biosystems or Agilent. Gene specific primers used were as follows: 
NP Forward: 5’-GTGTGCAACCTGCATTTTCTGT-3’ 
NP Reverse: 5’-TCTGAGGTTCTTCCCTCCGTATT-3’ 
PA Forward: 5’-GGACAAATGGAACATCAAAGATTAAA-3’ 
PA Reverse: 5’-CAGAAGACTCGGCTTCAATCATG-3’ 
Nxf1 Forward: 5’-CATGAGCTACCCCCACCAAT-3’ 
Nxf1 Reverse: 5’-CCCTTGCAGGGCGGTAA-3’ 
Crm1 Forward: 5’-GATCCACAGATGGTCGCTGAA-3’ 
Crm1 Reverse: 5’-CTCTAGCAGCTGGGACATTTCTC-3’ 
XpoT Forward: 5’-AGATGTTCATGCCCCTGCTT-3’ 
XpoT Reverse: 5’-ACTCCTCCGCAACATCTGCTT-3’ 
Xpo5 Forward: 5’-CCATCTTTGAACCCTGAATCAAG-3’ 
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Xpo5 Reverse: 5’-TAGAGATCGGCTACAAAGGGAAA-3’ 
UAP56 Forward: 5’-CAGACAGGCATTTTCCAAAGC-3’ 
UAP56 Reverse: 5’-CGCAAGGGACCGGAAAC-3’ 
URH49 Forward: 5’-GCTCCCCCTAAGAAAGACATCAA-3’ 
URH49 Reverse: 5’-TCCGGCTTCAGCAGAAAGTC-3’ 
 
Quantitative PCR Analysis 
Data was collected as CT values and analyzed using Microsoft Excel with 
the formula: 2(CT average control sample – CT average treated sample). All statistical analysis set 
p≤0.05 as significant. For samples with an equal number of data points, a two-
tailed paired T-test was performed. Error bars were calculated using the standard 
deviation of data set divided by the square root of the number of samples. 
 
Cell Viability 
Cells for this assay were transfected with siRNA SMARTpools targeting 
Nxf1, UAP56, DDX39 sequences, and a non-target scramble. Cells were imaged 
and assessed visually before performing a trypan blue exclusion assay. Cell 
viability was assessed using Countess FL II from Invitrogen. 48 hours post 
transfection, cells were collected by cell scraping and suspended in 1mL of 
DMEM with 10% FBS. A 50μL aliquot of cells was taken for assessment of 
viability using 0.4% Trypan Blue. Cells were mixed 1:1 with Trypan Blue and 
loaded into BioRad cell counting slides. 
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CHAPTER THREE 
CRISPR-MEDIATED KNOCKOUT OF UAP56 AND URH49 
 
Background 
We took advantage of Horizon Discovery’s free offer to test potential 
CRISPR guide RNAs against cellular factors of interest. We selected two 
candidates, UAP56 and URH49, to investigate how the absence of these RNA 
helicases might impact viral RNA expression. Influenza primarily infects lung 
tissue, so we chose to use A549 cells because they represent the most 
appropriate cell model for influenza infection. Horizon Discovery provided 10 
plasmids (5 different guide RNAs per gene target) encoding guide RNA, modified 
Cas9, and Dasher-GFP. These plasmids were used in transfection, according to 
the workflow shown in figure 1. 
 
Transfection of CRISPR Plasmids 
In addition to the CRISPR plasmids, which themselves encode GFP, we 
also transfected a separate sample of cells with eGFP, which allowed us to 
assess transfection efficiency separately. Transfection efficiency for eGFP was 
typically high, similar to the fluorescent microscopy image shown in figure 1. 
CRISPR plasmids typically had much lower transfection efficiencies, estimated to 
be less than 10%. 
 
27 
 
 
Figure 1 – CRISPR plasmid transfection workflow – A549 cells were seeded in a 
6-well plate before transfection. Mirus LT-1 transfection reagent was complexed 
with CRISPR plasmid and allowed to incubate with cells for 48-72 hours before 
harvesting.  
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Initial Testing Using Surveyor Nuclease 
Surveyor nuclease recognizes mismatched bases in double stranded 
DNA. We employed surveyor nuclease to assess whether the CRISPR plasmid 
guide RNAs were successful in targeting and creating null mutations in the target 
genes. 
To demonstrate Surveyor nuclease function, two control DNA from the 
purchased kit were PCR amplified within a region which differed only in the 
presence of a C nucleotide or G nucleotide. PCR products of 600 base pairs 
were amplified, mixed, denatured, and then allowed to hybridize. The hybrid 
products were aliquoted into separate tubes and Surveyor nuclease was added. 
At the intervals of 10, 20, 30, 45, and 60 minutes, stopping solution was added to 
prevent further nuclease activity. The digested products were run on an agarose 
gel and the minimum time required to observe cleavage bands was determined 
(figure 2). 
As control, the original PCR products were denatured and allowed to 
reanneal before incubation with surveyor nuclease for 60 minutes as a control for 
the enzyme’s exonuclease activity which competes with its mismatch 
endonuclease activity. Magnesium in the reaction tends to bias the enzyme 
toward its endonuclease activity as well. A small amount of smearing beneath the 
control samples indicate very slight exonuclease activity, given there is some 
smearing observed in the no nuclease control. In the reaction samples, specific 
cleavage bands are visible by 30-minute incubation of the mismatch, indicating 
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that endonuclease activity is preferred. No significant banding can be observed 
at 10 and 20 minutes, but is clearly visible from 30 minutes onward, with no 
improvement of endonuclease activity by 60 minutes. Therefore, we determined 
two things: (1) that 30 minutes is the minimum time required to observe bands 
and (2) that 45 minutes is the time point where maximal cleavage is observed. 
To assess CRISPR activity from the Horizon Discovery plasmids, DNA 
was extracted using the PureLink Genomic DNA mini kit from ThermoFisher. 
Genomic DNA, from both CRISPR-transfected cells and control cells, was used 
as a template in PCR to amplify both UAP56 and URH49 genomic DNA 
surrounding the CRISPR targeted region. PCR products from control and 
transfected cells were mixed together and denatured through heating. In a slow, 
step-by-step cooling process, the products re-anneal and if CRISPR worked, 
mismatches within the DNA duplex between control and CRISPR treated should 
produce a bubble at which Surveyor will cut. As a control, UAP56 PCR product 
and URH49 product were mixed, annealed and treated. In initial trials, no 
cleavage bands could be observed in PCR products amplified from cells 
transfected with any of the CRISPR plasmids. Given the low transfection 
efficiency, we reasoned most genomes remained intact and our PCR product 
would reflect this. Therefore, we decided to use Fluorescence Activated Cell 
Sorting (FACS) to select for the GFP-positive population which would yield a 
definitive answer to whether the Horizon Discovery designed plasmids targeted 
the intended genes of interest. 
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Figure 2 – Surveyor nuclease control test with C and G plasmid – lane 1: ladder; 
lane 2,3: pure control plasmid PCR product (600 base pairs) with no nuclease; 
lane 4-8: digest of hybridized control C and G products at 10, 20, 30, 45, and 60 
minutes; lane 9: denatured and re-annealed control C PCR product only in the 
presence of Surveyor nuclease for 60 minutes. Surveyor cleavage products 
expected at 200 and 400 base pairs are observed by 30 minutes, but most 
prominently after 45 minutes. 
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Cell Sorting with FACS 
Due to the low efficiency of transfection with the CRISPR plasmids in 
A549 cell, we sorted and collected GFP expressing cells to enrich for a 
population of cells with high levels of GFP expression, indicating the presence 
and expression of CRISPR plasmid. Cells were harvested by scraping, washed 
and suspended in a sorting buffer, and then transported on ice to the Institute for 
Integrative Genome Biology at University of California Riverside. 
FACS analysis was performed using different comparisons of forward 
scatter and side scatter to eliminate cellular debris and cellular doublets from the 
final isolated population and estimation of transfection efficiency. In figures 3-12, 
panel A displays time vs. forward scatter and demonstrates the constant flow of 
the FACS machine. While nearly all candidates demonstrated a relatively 
constant flow during sorting, candidate 15 did not. Most of. Panel B demonstrates 
the comparison of forward scatter vs. side scatter and is used to exclude cellular 
debris from the isolated population. In the bottom left corner of the field, a high 
density of events with small size (low forward scatter) and low complexity (low 
side scatter) indicates the presence of cellular debris. For further analysis, these 
events were excluded using a gate (red outline around the large cluster of 
events). Panel C demonstrates the comparison of forward scatter area vs. 
forward scatter height. Height, during sorting, is the intensity of the forward 
scatter signal. The area is a product of the height and width of the signal (how 
long it takes the cell to move through the detector). When cells are stuck 
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together, they do not cause an increase in signal height, but increase the width. 
As a result, the area increases without an increase in height. This comparison, 
ultimately, allows us to exclude doublets and clumps of cells, some of which may 
express GFP some may not. The blue gate, drawn around the cluster of cells 
moving diagonally up and to the right, indicates single cells. Panel D 
demonstrates a Principal Component Analysis (PCA), a mathematical 
transformation which group like populations together for easier identification of 
the GFP-positive population of cells. The PCA used forward scatter and GFP 
expression to show events that displayed higher intensities of GFP in single cells. 
The percentage of GFP-positive single cells ranged from 0.9% to 4.1%, 
confirming low transfection efficiency with CRISPR plasmids. From this we were 
able to isolate genomic DNA from only 5x104--2.2x105 cells.  
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Figure 3 – CRISPR plasmid candidate 14 (URH49) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. The lower corner is 
composed of cellular debris while the moderately dense region of events (green, 
light blue) within the gating are whole cells.  Panel C (FSC-A vs. FSC-H): Doublet 
exclusion of events. Panel D (PCA of FSC-A vs. GFP): PCA revealed that 0.9% 
of cells were GFP-positive. 
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Figure 4 – CRISPR plasmid candidate 15 (URH49) FACS analysis – Panel A 
(time vs. FSC-A) Disruptions at the start of FACS create a delay in the sorting 
process. When sorting begins (approx. 700 seconds), the process in slowed to 
ensure that clogging did not occur.  Panel B (FSC-A vs. SSC-A): Comparison of 
forward scatter and side scatter reveals two distinct populations of events. The 
gating around the large cluster of events indicates single cells.  Panel C (FSC-A 
vs. FSC-H): Doublet exclusion of events. Panel D (PCA of FSC-A vs. GFP): PCA 
revealed that 0.9% of cells were GFP-positive. 
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Figure 5 – CRISPR plasmid candidate 16 (URH49) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. Cellular debris in the lower 
left corner is excluded from analysis.  Panel C (FSC-A vs. FSC-H): Doublet 
exclusion of events. Panel D (PCA of FSC-A vs. GFP): PCA revealed that 1.4% 
of cells were GFP-positive. 
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Figure 6 – CRISPR plasmid candidate 17 (URH49) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. The lower corner is 
composed of cellular debris while other events within the gating are whole cells.  
Panel C (FSC-A vs. FSC-H): Doublet exclusion of events. Panel D (PCA of FSC-
A vs. GFP): PCA revealed that 4.1% of cells were GFP-positive. 
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Figure 7 – CRISPR plasmid candidate 18 (URH49) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. The lower corner is 
composed of cellular debris while other events within the gating are whole cells.  
Panel C (FSC-A vs. FSC-H): Doublet exclusion of events. Panel D (PCA of FSC-
A vs. GFP): PCA revealed that 3.1% of cells were GFP-positive. 
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Figure 8 – CRISPR plasmid candidate 29 (UAP56) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. The lower corner is 
composed of cellular debris while other events within the gating are whole cells.  
Panel C (FSC-A vs. FSC-H): Doublet exclusion of events. Panel D (PCA of FSC-
A vs. GFP): PCA revealed that 2.2% of cells were GFP-positive. 
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Figure 9 – CRISPR plasmid candidate 30 (UAP56) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. The lower corner is 
composed of cellular debris while other events within the gating are whole cells.  
Panel C (FSC-A vs. FSC-H): Doublet exclusion of events. Panel D (PCA of FSC-
A vs. GFP): PCA revealed that 3.1% of cells were GFP-positive. 
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Figure 10 – CRISPR plasmid candidate 31 (UAP56) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. The lower corner is 
composed of cellular debris while other events within the gating are whole cells.  
Panel C (FSC-A vs. FSC-H): Doublet exclusion of events. Panel D (PCA of FSC-
A vs. GFP): PCA revealed that 2.4% of cells were GFP-positive. 
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Figure 11 – CRISPR plasmid candidate 32 (UAP56) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. The lower corner is 
composed of cellular debris while other events within the gating are whole cells.  
Panel C (FSC-A vs. FSC-H): Doublet exclusion of events. Panel D (PCA of FSC-
A vs. GFP): PCA revealed that 3.2% of cells were GFP-positive. 
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Figure 12 – CRISPR plasmid candidate 33 (UAP56) FACS analysis – Panel A 
(time vs. FSC-A) Even distribution of events indicates that flow through FACS 
was constant. Panel B (FSC-A vs. SSC-A): Comparison of forward scatter and 
side scatter reveals two distinct populations of events. The lower corner is 
composed of cellular debris while other events within the gating are whole cells.  
Panel C (FSC-A vs. FSC-H): Doublet exclusion of events. Panel D (PCA of FSC-
A vs. GFP): PCA revealed that 3.2% of cells were GFP-positive. 
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Surveyor Nuclease Assay After FACS 
Genomic DNA was extracted from the GFP-positive population of cells 
(less than 10ng/uL for all samples) and used in PCR for the Surveyor nuclease 
assay. In the first run (figure 13), URH49 did not amplify from the genomic DNA 
template while UAP56 amplified strongly, displaying bands at the predicted 
length of 1100 base pairs. URH49 primers had previously been tested and were 
shown to amplify from genomic DNA very well, also producing bands at 1100 
base pairs, so this result was very unexpected. 
 A second attempt was made to amplify URH49 (figure 14). While UAP56 
failed to amplify in just one sample in this trial, amplification of URH49 produced 
bands indicating non-specific products. Specific amplification of URH49 varied 
from very weak to moderately strong. At this point, there was not enough 
genomic DNA to continue assessing URH49 candidates, so an effort was made 
to assess UAP56 candidates. 
UAP56 PCR products were analyzed using Surveyor nuclease (figure 15). 
The positive control with hybridized control C and G products did not appear to 
cut; making our results inconclusive. While we see banding at 600 base pairs in 
the UAP56 candidate lanes, indicative of nuclease activity, the size was 
unexpected for the predicted sizes expected to result from surveyor cleavage of 
the CRISPR directed gene edit and appeared instead to be indicative of the 
enzyme’s exonuclease activity. Surveyor has both endonuclease and 
exonuclease activity, but the buffer used for the assay tends to suppress 
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exonuclease activity while giving preference to the endonuclease activity. There 
was not enough genomic DNA to continue assessment of UAP56 candidates and 
given results were not promising, we did not pursue this approach further.  
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Figure 13 – Amplification of URH49 and UAP56 from GFP-positive population 
obtained through FACS – Lanes 2-6: URH49 candidates 14-18. Lane 7: 
Amplification of URH49 from untreated control cells. Lanes 8-12: UAP56 
candidates 29-33. Lane 13:  Amplification of UAP56 from untreated control cells. 
Lanes 14-15: Surveyor Control C and G. Amplification of URH49 and UAP56 
sequences should produce a band at 1100 base pairs while Control C and G 
sequences should appear at 600 base pairs. URH49 sequences did not appear 
to be amplified while UAP56 sequences showed strong amplification. Control C 
and G were also successfully amplified. A second PCR, in an attempt to amplify 
URH49 sequences, was performed as a follow up. 
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Figure 14 – Second attempt PCR to amplify URH49 and UAP56 from GFP-
positive population obtained through FACS – Lanes 2-6: URH49 candidates 14-
18. Lanes 7-11: UAP56 candidates 29-33. Amplified URH49 and UAP56 
sequences were expected at 1100 base pairs. Amplification of URH49 
sequences from candidates produced many non-specific bands while most 
UAP56 sequences were strongly amplified. We determined that there were too 
few cells obtained through FACS to give enough genomic DNA for amplification 
to occur. 
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Figure 15 – Surveyor nuclease assay of UAP56 plasmid candidates – PCR 
product from candidates was hybridized with product from untreated control cells 
and treated with Surveyor nuclease. Surveyor treatment did not appear to cut the 
positive control and UAP56 candidates had degradation at approximately 600 
base pairs. 
 
 
 
 
48 
 
Conclusions 
 Surveyor activity is clearly visible in control samples (figure 2), 
demonstrating its ability to discern the presence of mismatched bases in DNA. 
However, a mismatch is not likely to be observed if it is present in low 
abundance, an issue we observed when working with genomic DNA from a 
population of cells where transfection efficiency is low. This problem prompted 
the use of FACS to obtain a pure population of GFP-positive cells.  
Ultimately, sorting CRISPR-transfected cells through FACS did not yield 
enough GFP-positive cells to determine if CRISPR was active and effectively 
targeting the genes of interest. Analysis of sort data using FSC-A vs. SSC-A, 
FSC-A vs. FSC-H, and PCA revealed transfection efficiencies as low as 0.9% 
and no higher than 4.1%.  
PCR using genomic DNA extracted from these GFP-positive populations 
and analysis with Surveyor nuclease did not yield definitive results. While we did 
not detect surveyor endonuclease activity on our samples, the positive control in 
that trial did not work, leaving our data uninterpretable. Unfortunately, we did not 
recover enough DNA to repeat. Given the lack of promising data regarding the 
effectiveness of the CRISPR plasmids, we decided to employ a method utilizing 
small interfering RNAs (siRNAs) to assess the impact of UAP56, URH49, and 
export factor knockdown on viral replication. 
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CHAPTER FOUR 
SMALL INTERFERING RNA 
 
Background 
RNA interference is a proven method to downregulate target gene 
expression. Indeed, there are commercially available small interfering RNAs 
guaranteed to target specific host genes with no off-target effects.   We 
purchased SMART-pool siRNAs to evaluate the effect of knockdown of various 
host factors including the RNA helicases UAP56 and URH49, and the nuclear 
export factors Xpo5 and XpoT on viral RNA expression. 
 
Export Factor Knockdown 
Since influenza vRNPs express and replicate the genome in the nucleus, 
we were interested in the role of nuclear export factors in viral replication. Nxf1 is 
essential for successful influenza infection, as siRNA inhibition results in cell 
death and little infection (Larsen). Partial inhibition of Nxf1 did allow for 
permissive influenza infection and demonstrated that some, but not all, influenza 
mRNAs export from the nucleus via Nxf1 (Larsen et. al). Crm1 on the other hand 
is not involved in influenza mRNA nuclear export (Larsen) but is required for 
vRNP nuclear export during virion assembly (Neumann et al., 2000). Little is 
known regarding the possible role of additional host export factors Xpo5 and 
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XpoT.  We aimed to determine if inhibition of these factors might inhibit viral 
replication. 
In both A549 and Vero cells, XpoT and Xpo5 siRNAs were used to knock 
down their respective targets. In A549 cells (figure 16), knockdown is both robust 
and specific, reducing expression to less than 10% of normal. Expression of NP 
and PA was assessed and there was no significant change in the expression of 
either of these viral RNAs in either knockdown. 
In Vero cells, Xpo5 and XpoT knockdown was specific and resulted in 
expression of less than 20% of normal (figure 17). Again, expression NP and PA 
was assessed and there was no significant change in the expression of either of 
the viral RNAs in either knockdown. 
We can conclude from these data that Xpo5 and XpoT do not appear to 
have any significant impact on viral RNA expression at early timepoints of 
infection (within 4 hours post-infection). 
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Figure 16 – siRNA targeting Xpo5 and XpoT and Influenza infection in A549 
cells, with Pedro Medina –  A. RNA was resolved on 1% bleach/agarose gel to 
ensure equal concentration and integrity. Two trials were selected for each 
sample to analyze in triplicate by RT-qPCR. Xpo5 and XpoT siRNA effectively 
knocked down their respective targets. There were no significant differences in 
NP or PA expression when either of these factors were knocked down, 
suggesting that they do not play an important role early during infection. Data 
obtained is from duplicate trials. Significance was determined with Student’s Test 
using P < 0.05. 
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Figure 17 – siRNA targeting Xpo5 and XpoT and Influenza infection in Vero cells, 
with Pedro Medina – RNA was resolved on 1% bleach/agarose gel to ensure 
equal concentration and integrity. Two trials were selected for each sample to 
analyze in triplicate by RT-qPCR RNA as indicated was subject to RT-qPCR as 
indicated. Target siRNA results in Xpo5 expression at 15% of normal and XpoT 
expression reduced to 3% of normal. No cross-reactivity of siRNA was observed. 
There was no significant effect of Xpo5 or XpoT knockdown on influenza RNA 
expression of NP or PA. Data obtained is from duplicate trials.  Significance was 
determined with Student’s T-Test and P < 0.05. 
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UAP56 and URH49 Knockdown 
UAP56 and URH49 have been implicated in separate studies to interact 
with the viral nucleoprotein (NP) and enhance viral RNA synthesis (Kawaguchi; 
Wisskerchen). Interestingly, only UAP56, and not URH49, was shown involved in 
unwinding dsRNA to limit the host innate interferon response (Wisskerchen). Our 
goal was to clarify the roles of these host factors and determine if either could 
serve as an antiviral target and inhibit influenza replication without harming self. 
A549 cells were transfected with siRNA against UAP56 or DDX39, 
targeting both DEAD-box helicases URH49 and UAP56, also known as DDX39A 
and DDX39B, respectively. At 48 hours post transfection, cells were infected with 
Influenza A at a high multiplicity of infection to observe effect of host knockdown 
on a single infection cycle. We aim to inhibit an early stage of viral RNA 
replication and therefore isolated RNA at 4 hours post infection to assess viral 
RNA expression. RNA concentration was taken and equal concentration resolved 
on 1% agarose bleach gel (Figure 18). Reverse transcription followed by 
quantitative PCR confirms target knockdown for UAP56 and both UAP56 and 
URH49 when DDX39 siRNA is used. UAP56 was successfully knocked-down in 
only one trial, revealing a decrease in viral NP RNA expression, at about 25% of 
non-target siRNA treated control cells. Interestingly, UAP56 inhibition resulted in 
a concomitant URH49 increase. Inhibition of both UAP56 and URH49 also 
results in severe reduction in viral RNA expression. NP and PA RNA were 
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reduced to about 20% compared to non-target siRNA treated control cells and 
depending on how well URH49 was inhibited (Figure 18 and data not shown). 
To determine if inhibition is due to UAP56’s reported unwinding of dsRNA 
products, resulting in decreased host antiviral interferon response to improve 
viral replication, we repeated the siRNA analysis in VERO cells, which lack 
interferon. Similar to A549 cells, we see a decrease in both NP and PA 
expression when DDX39 is inhibited (figure 19). However, we did not detect 
expression of UAP56 in the non-target treated VERO cells, and therefore did not 
see reduction in expression when siRNA against UAP56 was transfected. We 
conclude the host factors have an interferon-independent effect on viral RNA 
expression. Further, we speculate VERO cells may rely more heavily on URH49 
as UAP56 expression was not detected.  
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Figure 18 – siRNA targeting UAP56 and DDX39 and Influenza infection in A549 
cells. – General DDX39 siRNA significantly reduced the expression of UAP56 
and URH49. UAP56 siRNA was specific and also significantly reduced 
expression of its target. UAP56 siRNA caused a significant increase in URH49 
expression to 150% of normal. Knockdown of UAP56 and URH49 resulted in 
significantly reduced expression of NP viral RNA. Results shown are qPCR 
triplicate data from one trial. Significance was determined with Student’s T-Test 
and P < 0.05. RNA integrity data not shown. 
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Figure 19 – siRNA targeting DDX39 and Influenza infection in Vero cells – RNA 
was resolved on 1% bleach/agarose gel to ensure equal concentration and 
integrity. DDX39 siRNA successfully knocked down expression of URH49 to 30% 
of normal. UAP56 was not detected above no RT control in VERO cells. DDX39 
siRNA significantly reduced NP and PA expression. Significance was determined 
using Student’s T-Test with P < 0.05. 
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Viability Assay 
To determine whether UAP56 or URH49 could be reasonable targets 
within the host to combat Influenza infection, a viability assay was conducted to 
assess the toxicity of downregulation of UAP56 or UAP56 and URH49 in A549 
cells. Cells transfected with siRNA were observed under the microscope at 48 
hours post transfection. Nxf1 siRNA was previously observed to cause a high 
degree of cell death, and served as control for a highly toxic treatment. 
Conversely, non-targeted siRNA should only demonstrate toxicity caused by the 
transfection reagent and served as the healthy control. 
As expected, cells incubated with Nxf1 siRNA displayed a high degree of 
cell death. At times, cellular debris obscures more than 50% of the visual field 
(figure 20, panel A-C). UAP56 siRNA-treated cells have similar cell death 
compared to non-target control based on microscopy images (panel D-F). 
DDX39 siRNA-treated cells (panel G-I) appeared to have similar, perhaps slightly 
more, cell death compared to UAP56 and the non-target control (panel J-L). 
Overall, based on the visual inspection, UAP56 knockdown appears to be 
relatively non-toxic. 
 Trypan blue exclusion was attempted to determine the percent live count 
of cells as a measure of toxicity between the samples. This analysis revealed 
great variability between triplicates and the data contradicted the visual 
microscopy assessment, indicating the non-target treated cells had the most cell 
death (Figure x). Based on our analysis we conclude that while inhibition of these 
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RNA helicases inhibits viral RNA expression, we do not observe massive cell 
death as seen with targeting an essential host factor such as Nxf1.  
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Figure 20 – Visual assessment of siRNA-treated A549 cells – Panel A-C: Nxf1 
siRNA, control for high degree of cell death. Panel D-F: UAP56 siRNA. Panel G-
I: DDX39 siRNA. Panel J-L: non-target siRNA, control for baseline cell death due 
to transfection reagent. 
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Conclusions 
RNA interference allowed us to inhibit host factors and examine the effect 
on influenza viral RNA expression. From our results, we conclude neither Xpo5 
nor XpoT contribute to viral RNA expression at early time points. There is no 
significant change in viral RNA expression when either of these factors is 
targeted. However, our data does supporting a role for host RNA helicases 
UAP56 and URH49 for optimal viral RNA expression. Targeted knockdown of 
UAP56 and URH49 results in reduced viral RNA expression in both A549 and 
VERO cells, indicating these factors play an interferon-independent role in viral 
RNA expression.  
To determine if these factors are essential to the host cell, we used visual 
microscopy to assess A549 cells 48 hours post transfection with targeted 
siRNAs. Cells display a high degree of cell death when treated with Nxf1 siRNA. 
UAP56 and DDX39 siRNAs produce little to no additional toxicity compared to 
the non-targeted control. This suggests that targeted inhibition of UAP56 or 
URH49 may prove to be a relatively non-toxic treatment to combat Influenza 
infection. Consistent with redundant roles for these host factors, our results with 
VERO cells suggest they do not even express UAP56.  
While it would have been preferable to collect quantitative data on cell 
viability, the assay encountered a major problem: the live counts associated with 
our highly-toxic control siRNA (Nxf1) had the highest percent-live counts while 
the non-toxic non-target control had the lowest percent live counts. I theorize that 
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the transfection reagent could be at fault here. Transfection reagent tends to 
have a low level of toxicity, but this toxicity may cause the cells to less-effectively 
efflux the trypan blue dye (whether due to faster penetration of the dye through 
the plasma membrane or by slower activity of efflux pumps) and appear to be 
“dead” to cell counters. Therefore, vital assays on cells subjected to transfection 
reagent as a means to introduce RNA or plasmids may require a method that 
does not rely on dyes in order to more-accurately discern live versus dead cells.  
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CHAPTER FIVE 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary 
Influenza A is a highly pathogenic, negative-sense, single-stranded RNA 
virus of the Orthomyxoviridae family that is the causative agent of seasonal and 
pandemic flu. Vaccination, while highly effective in protecting against other 
disease-causing agents, is relatively ineffective and inconsistent in its protective 
capabilities due to the high degree of mutation associated with the inherent low 
fidelity of RNA polymerases and the virus’ ability to re-assort. Additionally, 
antiviral treatments for Influenza infection are likely to become ineffective due to 
the development of resistance. In fact, resistance has already been observed. 
This means that developing new treatments for Influenza infections will be crucial 
for public health until a universal vaccine is developed. 
Previous studies have implicated UAP56 and URH49, host RNA 
helicases, in viral replication. While they likely serve primarily redundant 
functions in the host, they are reported to have varied functions during viral 
infection. Here we demonstrate they have IFN independent effects on viral RNA 
expression; in particular, if both are inhibited, there is significant impact on viral 
RNA expression. While UAP56 is thought to be important for host mRNA export, 
we see no significant cell death 48 hours post transfection with siRNA inhibiting 
UAP56 or UAP56 and URH49, suggesting there may be additional DEAD-Box 
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RNA helicases that can function as DDX39.  It is this redundancy of function in 
the host but centrality for viral replication that makes UAP56 and URH49 prime 
targets for development of a novel antiviral therapy. 
While CRISPR did not yield cell lines null for UAP56 or URH49, siRNA 
studies found several important things about the role of these RNA helicases in 
Influenza viral RNA expression. Knockdown of host RNA helicases UAP56 or 
DDX39 (UAP56 and URH49) provided additional evidence to support a role for 
UAP56 and URH49 to enhance viral RNA expression. We found that these RNA 
helicases are important for viral RNA expression even in the absence of a host 
IFN response, as observed in Vero cells.   
Visual assessment of cell death over three separate trials indicated that 
UAP56 siRNA treatment was similar to the relatively non-toxic non-targeted 
treatment. This provides some evidence that UAP56 may indeed be a viable 
target for novel antiviral therapy. 
Given that influenza virus replicates in the nucleus, we also analyzed the 
effect of inhibiting host nuclear export factors prior to influenza infection. Our 
results here revealed that inhibition of  Xpo5 (miRNA export) or XpoT (tRNA 
export) in either A549 or Vero cells has no significant effect on viral NP and PA 
expression. Targeted knockdown of these factors did not cause any significant 
change in viral RNA synthesis at early stage of the viral lifecycle. Therefore, 
these host factors are not as promising targets for development of novel antiviral 
therapies as the DDX39 helicases. 
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Future Directions 
 While CRISPR attempts did not generate a null cell line, it may be 
possible for future work to be done in commercially available knockout cell lines 
already established as knockout of UAP56 or URH49. While siRNA has shown to 
be effective in knocking down gene expression of specific targets, knock down 
can be inconsistent and range from near complete knockdown to only 25% 
knockdown of the same target depending on experiment (for example, see 
chapter 4: figures 16 and 19). Purchasing a knockout cell line would eliminate 
much of the variability from the method. 
 While Nxf1 plays a major role during influenza infection, it is also an 
essential host factor and as such would not be a good target for novel antivirals. 
Analysis of the additional members of the Nxf group of export factors, including 
Nxf2, Nxf3, Nxf4, and Nxf5, may reveal novel roles and activities for these host 
factors and may define them as possible host targets to inhibit viral replication.  
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